BioPharmaPT
← All reports

Roche Holding AG — Columvi EMA EPAR public assessment report (EMEA/H/C/005751, 2023)

Roche Holding AG · 2023 · EMA EPAR public assessment report · company profile →

Report summary

The European Medicines Agency (EMA) assessed Columvi (glofitamab) for conditional marketing authorization as monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The T-cell bispecific antibody demonstrated acceptable quality, and preclinical studies showed dose-dependent tumor cell lysis and anti-tumor activity. Clinical efficacy from Study NP30179, Cohort D3, revealed a 35.2% complete response rate with a median duration of response of 14.4 months in heavily pre-treated patients. Key safety concerns include cytokine release syndrome (CRS), blood disorders, and infections, which are generally manageable. Columvi offers a potential benefit, including for patients who failed CAR-T therapy, and the CHMP recommended conditional marketing authorization.

Key findings — cited to the page

Grade ≥ 2 ALT, AST, or total bilirubin elevation7.1 %glofitamab · p.123
Grade 3 TLS AE1.3 %glofitamab · p.122
Grade ≥ 3 febrile neutropenia2.6 %glofitamab · p.122
Grade ≥ 2 CRS AEs (ASTCT 2019)41/195 glofitamab · p.116
Grade ≥ 2 neurological AE14.3 %glofitamab · p.121
Grade ≥ 2 NAEs16.4 %glofitamab · p.121
CRS AEs of any grade (ASTCT 2019)64.3 %glofitamab · p.114
Tumour flare of any grade11.0 %glofitamab · p.120
CRS AEs of any grade (ASTCT 2019)66.1 %glofitamab · p.114
Grade ≥ 2 CRS AEs (ASTCT 2019)16.2 %glofitamab · p.116
Tumour flare ≥ Grade 27.1 %glofitamab · p.120
CRS AEs of any grade (Lee et al 2014)66.9 %glofitamab · p.141

Source: Roche Holding AG · License: EMA - reuse permitted with acknowledgement. Summary and findings are extracted from the published document; every figure cites its page. Informational only — not investment advice. Explore the Oncology library →

Roche Holding AG — Columvi EMA EPAR public assessment report (EMEA/H/C/005751, 2023) — Summary & Key Findings | BioPharmaPT